Screener / SEC EDGAR /CIK 0001819790 /10-K filed Feb 23, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Tarsus Pharmaceuticals, Inc. TARS

Compare with peers Embed
The 10-K against last year's

207 changes: 36 added, 48 removed, 118 reworded, 5 quiet changes

10-K Feb 23, 2026 vs Feb 25, 2025

10-K 0001819790-26-000019 (Feb 23, 2026) vs 10-K 0001819790-25-000011 (Feb 25, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

546 paragraphs · 25 new · 127 reworded · 8 gone · 10-K Feb 23, 2026 against Feb 25, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 276 · 47% changed Every version of it
The rules dealing with U.S. federal, state, and local income taxation are complex and are constantly under review by legislators, the U.S. Department of Treasury, and the Internal Revenue Service. Changes to tax laws (which may have retroactive application) have occurred and are likely to continue to occur in the future, which could adversely affect our shareholders. For example, the Internal Revenue Code tax capitalization rules operative beginning in 2022 required that domestically incurred research and development expenses be capitalized and amortized over a 5-year period for tax purposes. However, The One Big Beautiful Bill Act (the “OBBB Act”), enacted in July 2025, features several tax reforms, including permitting taxpayers to permanently deduct domestic research and development expenses for amounts paid or incurred in tax years beginning after December 31, 2024. The primary impact of the OBBB Act on our U.S. Federal tax provision is the accelerated expensing of domestic R&D activities which reduces our deferred tax assets and valuation allowance. At the state level, domestic R&D expenditure continues to be capitalized and amortized in jurisdictions that do not conform to the federal provisions of the OBBB Act, which results in an increase in our state tax provision.
Paragraph 262 · 45% changed Every version of it
Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in March 2023, Silicon Valley Bank ("SVB") (“SVB”) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC"), (“FDIC”), as receiver, and SVB was subsequently transferred into a new entity, Silicon Valley Bridge Bank ("SVBB"). In March 2023, (“SVBB”) which First Citizens Bank assumed all of SVBB’s obligations and commitments, and SVBB began operating as SVB, a division of First Citizens Bank. Unless otherwise noted herein, all references to SVB or Silicon Valley Bank shall refer to Silicon Valley Bank, a division of First Citizens Bank. In light of the foregoing, the Company does not believe it has exposure to loss as a result of SVB’s receivership. then assumed.
Paragraph 354 · 45% changed Every version of it
If we enter into in-bound intellectual property license agreements, we may not be able to fully protect the licensed intellectual property rights or maintain those licenses. In each of the Elanco Agreements, Elanco retains, and future licensors could retain, the right to prosecute and defend the intellectual property rights licensed to us, in which case we would depend on the ability of our licensors to obtain, maintain and enforce such licensed intellectual property. These licensors may determine not to pursue litigation against other companies or may pursue such litigation less aggressively than we would. If our licensors do not adequately protect such licensed intellectual property, competitors may be able to use such intellectual property and erode or negate any competitive advantage we may have, which could materially harm our business, negatively affect our position in the marketplace, limit our ability to commercialize our products and product candidates and delay or render impossible our achievement of profitability. Further, entering into such license agreements could impose various diligence, commercialization, royalty or other obligations on us. Future licensors may allege that we have breached our license agreement with them, and accordingly seek to terminate our license, which could adversely affect our competitive business position and harm our business prospects.
Paragraph 306 · 43% changed Every version of it
The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.
Paragraph 434 · 42% changed Every version of it
Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011 and subsequent laws. Subsequent legislation extended the 2% reduction, generally to 2031. Sequestration is currently set at 2% and will increase to 2.25% for the first half of fiscal year 2030, to 3% for the second half of fiscal year 2030, and to 4% for the remainder of the sequestration period that lasts through the first six months of fiscal year 2031. The American Taxpayer Relief Act of 2012 among other things, also reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. New laws may result in additional reductions in Medicare and other healthcare funding, which may materially adversely affect customer demand and affordability for our products and related services and, accordingly, the results of our financial operations. Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP
Paragraph 382 · 41% changed Every version of it
Competitors may infringe, misappropriate or otherwise violate our patents, trademarks, copyrights or other intellectual property. It may be difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor’s or potential competitor’s product. To counter infringement or unauthorized use, we may be required to file infringement or other intellectual property-related claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. There can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from making, using, or selling the invention at issue. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld material information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). The outcome following legal assertions of invalidity and unenforceability is unpredictable. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent’s claims narrowly or decide that we do not have the right to stop the other party from making, using or selling the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks, which could materially harm our business and negatively affect our position in the marketplace.
Paragraph 427 · 40% changed Every version of it
Moreover, early positive preclinical or clinical trial results may not be replicated in later clinical trials. As more product candidates within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Failure to demonstrate adequately the quality, safety and efficacy of any of our product candidates would delay or prevent marketing approval of the applicable product candidate. We cannot assure you that if clinical trials are completed, either we or our potential collaborators will submit applications for required authorizations to manufacture or market potential products or that any such application will be reviewed and approved by appropriate regulatory authorities in a timely manner, if at all. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application.
Paragraph 231 · 38% changed Every version of it
In connection with our in-license, out-license, or other collaborations or strategic alliances, we may agree to and be bound by negative covenants which may limit our development and commercial opportunities. For example, pursuant to the Elanco Agreements, we made certain covenants to only engage with third party suppliers previously approved by Elanco, and only under certain circumstances. These provisions may inhibit our development efforts, prevent us from forming strategic collaborations to develop and potentially commercialize any other product candidates and may materially harm our business, financial condition, results of operations and prospects.

MD&A

93 paragraphs · 11 new · 50 reworded · 40 gone · 10-K Feb 23, 2026 against Feb 25, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 18 · 49% changed
In March 2023, we initiated the Galatea trial, a Phase 2a trial evaluating TP-04, a novel gel formulation After review of lotilaner, for the treatment of rosacea. In February 2024, we announced positive topline results from the Galatea trial evaluating TP-04 for the treatment of rosacea which demonstrated statistically significant improvements (p<0.05) in inflammatory lesions and Investigator's Global Assessment score (change in baseline and success rate) were observed compared to vehicle at week 12. TP-04 was generally well tolerated. After review of this data with the FDA and Key Opinion Leaders, key opinion leaders (“KOLs”), we decided to pursue development of TP-04 for the potential treatment for Ocular Rosacea. ocular rosacea, a highly prevalent and underserved eye disease with no FDA-approved therapy. In January December 2025, we announced plans to initiate initiated a Phase 2 study in the second half of 2025 trial for the potential treatment of Ocular Rosacea. ocular rosacea with topline results expected in the first half of 2027.
Paragraph 76 · 47% changed
Our operating lease commitments reflect payments due for our active lease agreements agreement in Irvine, California, for adjacent office and laboratory suites. In December 2024, we entered into a lease agreement for office space located in Irvine, California for a 10-year lease term. The lease payments are expected to commence in late 2025 following the earlier of: (i) eleven months following the lease execution date, or (ii) the date the Company commences its regular business activities at the premises following completion of tenant improvements. The base rent for the first year of the lease will be approximately $2.5 million and is subject to annual increases of 3% thereafter. The Company is entitled to an abatement of base rent for the first five full calendar months from the beginning of the lease commencement date for an aggregate amount of $0.7 million. As of December 31, 2024, 2025, our contractual commitments for our leases were $0.8 $28.4 million, which will be paid over the a remaining lease term of 0.8 9.9 years.
Paragraph 39 · 43% changed
See the section titled "Risk Factors" for a further discussion of For additional information regarding the potential adverse impact effects of unfavorable global and geopolitical economic conditions on our business, results of operations and financial condition. condition, please see “Risk Factors” in Item 1A of Part I of this Annual Report on Form 10-K.
Paragraph 22 · 42% changed
We •In Europe, we are on track for the potential European regulatory approval of a preservative-free formulation of XDEMVY TP-03 for the potential treatment of Demodex blepharitis expected in 2027. We have initiated market development work, including Key Opinion Leader engagement, disease education and scientific presentations at major conferences.
Paragraph 41 · 41% changed
Product sales, net increased by $165.3 million for During the year ended December 31, 2024 to 2025 and 2024, we recognized $451.4 million and $180.1 million, as compared to the prior year period. respectively from product sales, net of rebates, chargebacks, discounts, and other adjustments. This increase was primarily driven by more than 163,000 approximately 400,000 bottles of XDEMVY dispensed delivered to patients, patients during the year ended December 31, 2025, compared to 17,400 approximately 163,000 bottles dispensed delivered to patients in the prior year period. XDEMVY was approved period, as well as an increase in net sales price compared to the prior period driven primarily by an improvement in the FDA gross-to-net discount as we secured greater payer coverage in July 2023 and was commercially launched in August 2023. 2025.
Paragraph 42 · 39% changed
For During the year ended December 31, 2025, we did not recognize any license fees and collaboration revenue. During the year ended December 31, 2024, we recognized $2.9 million of license fees and collaboration revenue including (i) $2.5 million for the Termination Payment a termination payment related to the Novation Agreement, and (ii) $0.4 million for the Warrant Termination Payment. For the year ended December 31, 2023, we recognized $2.7 million related to (i) the achievement of a $2.5 million contractual milestone under the China Out-License, and (ii) $0.2 million from the satisfaction of performance obligations under an existing clinical supply agreement. These allocated amounts represented the satisfaction of the transfer of license rights to LianBio and the completion of related performance obligations. warrant termination payment (see Note 10).
Paragraph 46 · 38% changed
Other income, income (expense), net decreased increased by $2.2 $1.6 million for the year ended December 31, 2024 2025, primarily due to (i) $1.9 million of loss on debt extinguishment related to the termination of our 2022 Credit Facility (defined below), (ii) $4.5 million of increased interest expense related to Facility, which was recognized in the Credit Facilities, (iii) a $0.9 million decrease related to the change in fair value of the LianBio common stock sold in June, prior year period, and (iv) a $0.3 million decrease related to the change in fair value related to the final mark-to-market adjustment on the unvested third tranche equity warrant. These decreases were partially offset by (i) $4.7 $0.7 million of increased interest income earned on our cash, cash equivalents and marketable securities, and (ii) $0.7 securities. These increases were partially offset by $1.1 million of dividend income from LianBio. increased interest expense related to our 2024 Credit Facility.
Paragraph 26 · 35% changed
To date date, we have financed our operations through private placements of preferred stock, convertible promissory notes, net proceeds from issuance of common stock in our Initial Public Offering ("IPO"), initial public offering (“IPO”), our subsequent follow-on public offerings in May 2022 (the "May “May 2022 Public Offering"), Offering”), August 2023 (the "August “August 2023 Public Offering"), and Offering”), March 2024 (the "March “March 2024 Public Offering", Offering”), and March 2025 (the “March 2025 Public Offering”, collectively the "Follow-On “Follow-On Public Offerings"), Offerings”), and our Open Market Sale AgreementTM (the "2023 “2023 ATM Prospectus"), Prospectus”), as well as proceeds from net product sales, our China Out-License, and drawdowns from the loan and security agreement (the “2024 Credit Facilities. Facility”) with funds associated with Pharmakon Advisors, LP (“Pharmakon”), and the previous loan and security agreement with Hercules Capital, Inc. and Silicon Valley Bank, a division of First Citizens Bank & Trust Company (the “2022 Credit Facility”, and collectively the “Credit Facilities”).

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors365 words changed in this paragraph; it is 46% similar to last year's version.
We are exposed to the risk of fraud or other misconduct by our employees, clinical trial investigators, CROs, consultants, vendors and any potential commercial partners. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i) FDA laws and regulations or those of comparable foreign regulatory authorities, including those laws that require the reporting of true, complete and accurate information, (ii) manufacturing standards, (iii) federal and state health and data privacy, security, fraud and abuse, government price reporting, transparency reporting requirements, and other healthcare laws and regulations in the U.S. and abroad or (iv) laws that require the true, complete and accurate reporting of financial information or data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply be in compliance with such laws or regulations. We adopted a code of conduct applicable to all of our employees immediately following the completion of our IPO, as well as a disclosure program and other applicable policies and procedures, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, Medicaid and other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual programs, imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

Source: Item 1A, 10-K 0001819790-26-000019 vs Item 1A, 10-K 0001819790-25-000011

Accounting Policies159 words changed in this paragraph; it is 61% similar to last year's version.
Stock awards granted typically have one to four-year service conditions and a contractual term of 10 years. Any performance conditions for vesting are explicitly stated in each award agreement and are associated with clinical, business development, or operational milestones. For stock-based awards that vest subject to the satisfaction of a service requirement, the related expense is recognized on a straight-line basis over each award’s actual or implied vesting period. For stock-based awards that vest subject to a performance condition, the Company recognizes related will recognize compensation expense on an accelerated attribution method, if and when it concludes that performance conditions are achieved or when the Company determines it is highly probable that the performance condition conditions will be achieved. achieved by the end of the requisite service period. Compensation expense will be recognized on a cumulative catch-up basis in the period of achievement, and on a straight-line basis thereafter until the end of the requisite service period. The expense recognized for awards is based on the grant date fair value of a unit multiplied by the number of units expected to be earned with respect to the related performance conditions. Depending on the outcome of these performance goals, a recipient may ultimately earn a number of units greater or less than the number of units expected to be earned. Shares of the Company’s common stock are issued on a one-for-one basis for each performance unit earned. In general, performance unit awards vest at the end of the performance period. At each reporting period, the Company reassesses the probability of the achievement of the performance vesting conditions. As applicable, the Company reverses previously recognized expense for unvested awards in the same period of forfeiture.

Source: Item 8, Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES, 10-K 0001819790-26-000019 vs Item 8, Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES, 10-K 0001819790-25-000011

Legal Proceedings151 words changed in this paragraph; it is 57% similar to last year's version.
In December 2024, not yet been relocated. Construction remains in progress on the new facility and the Company entered into plans to relocate its headquarters during 2026. Lease payments under the New Current Lease agreement for 59,626 square feet of office space located began in Irvine, California for a 10-year lease term. The lease payments are expected to commence in late 2025 following November 2025. Base rent under the earlier of: (i) eleven months following the lease execution date, or (ii) the date the Company commences its regular business activities at the premises following completion of tenant improvements. The base rent Current Lease is $2.5 million for the first year of the lease will be $2.5 million and is subject to annual increases of 3% thereafter. The Upon commencement of the Current Lease, the Company is became entitled to an abatement of base rent abatement for the first five full calendar months from the beginning of the lease commencement date for an aggregate amount of $0.7 million. The lease Current Lease also provides for a tenant improvement allowance, not to exceed $6.0 approximately $5.8 million, and to be applied to the toward construction costs of the premises. The tenant improvement allowance must be used within one year of the Company commencing its regular business activities otherwise it Current Lease commencement date, after which any unused portion will be forfeited with no further obligation by the landlord. As of December 31, 2024, no rent payments were made and 2025, the landlord had not provided paid any of the tenant improvement allowance.

Source: Item 3, via Note 9 – COMMITMENTS & CONTINGENCIES, 10-K 0001819790-26-000019 vs Item 3, via Note 9 – COMMITMENTS & CONTINGENCIES, 10-K 0001819790-25-000011

MD&A123 words changed in this paragraph; it is 42% similar to last year's version.
Our operating lease commitments reflect payments due for our active lease agreements agreement in Irvine, California, for adjacent office and laboratory suites. In December 2024, we entered into a lease agreement for office space located in Irvine, California for a 10-year lease term. The lease payments are expected to commence in late 2025 following the earlier of: (i) eleven months following the lease execution date, or (ii) the date the Company commences its regular business activities at the premises following completion of tenant improvements. The base rent for the first year of the lease will be approximately $2.5 million and is subject to annual increases of 3% thereafter. The Company is entitled to an abatement of base rent for the first five full calendar months from the beginning of the lease commencement date for an aggregate amount of $0.7 million. As of December 31, 2024, 2025, our contractual commitments for our leases were $0.8 $28.4 million, which will be paid over the a remaining lease term of 0.8 9.9 years.

Source: Item 7, 10-K 0001819790-26-000019 vs Item 7, 10-K 0001819790-25-000011

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of TARS's Risk Factors and MD&A, 10-K Feb 23, 2026 against 10-K Feb 25, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
Our future financial performance and our ability to develop, manufacture and commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
Additionally, the U.S. government has made statements and taken certain actions including the imposition of tariffs, that have led to changes in U.S. and international trade policies towards China and other countries. It remains unclear what additional actions, if any, will be taken by the U.S. or other governments with respect to international trade agreements, the imposition of tariffs on goods imported into the United States, tax policy related to international commerce, or other trade matters or whether the imposition of tariffs will be upheld by courts or other governmental bodies. For example, on February 20, 2026, the U.S. Supreme Court struck down the international tariffs imposed by President Trump in 2025, but President Trump subsequently expressed his intent to reinstate the tariffs through other means, which he has not yet disclosed. We are closely monitoring changes and developments in international trade policy and assessing the potential impact of these and other trade policy changes on our business operations and financial performance. XDEMVY is currently being filled and finished by a reputable contract manufacturer in Europe, and we are in discussions to potentially add a second contract manufacturer domiciled in the U.S. If tariffs are imposed on any products we import, we believe the potential impact will be insignificant to our gross margins or other operating expenses.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
Any unfavorable government policies on international trade, such as capital controls or tariffs, or any countermeasures imposed in response thereto, may negatively affect the demand and competitive position of our product or future products to the extent any of our product candidates are approved for commercial sale, negatively affect our costs, or negatively impact our supply chain, among other potential negative impacts. If any tariffs are reinstated, any new tariffs, legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or, in particular, if the U.S.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
government, or other governments take retaliatory trade actions due to the recent trade tensions, including U.S.-China trade tensions, such changes could have an adverse effect on our business, financial condition and results of operations.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
We received approval by the FDA for XDEMVY for the treatment of Demodex blepharitis in the U.S. and began generating revenue from product sales during the third quarter of 2023. Our ability to become and remain profitable is heavily
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
A further example of comprehensive and evolving regulatory requirements is data privacy regulations surrounding personal data and protected health information including the EU’s General Data Protection Regulation, or GDPR, which imposes strict requirements on controllers and processors of personal data, including special protections for “special category data,” which includes health, biometric and genetic information of data subjects located in the EEA and UK. Further, the GDPR provides a broad right for EEA Member States to create supplemental national laws, such as laws relating to the processing of health, genetic and biometric data, which could further limit our ability to use and share such data or could cause our costs to increase, and harm our business and financial condition. Furthermore, there are evolving European privacy laws on electronic marketing and cookies.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the
Read it in 10-K Feb 23, 2026 at sec.gov
Show the other 64
AddedRisk Factors
Our reliance on these third parties for such development activities will reduce our control over these activities but will not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
materials to manufacture our products and product candidates, we may experience delays in our commercialization and development efforts, which would have an adverse effect on our business and results of operations.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
delay commercialization efforts of XDEMVY or any future products, if approved, clinical development of product candidates or marketing approval of current or future product candidates.
Read it in 10-K Feb 23, 2026 at sec.gov
RemovedRisk Factors
CMOs and other suppliers are subject to inspection by the FDA and may receive observations that they may not be able to resolve in a timely or effective manner, which could impact whether our products can be approved on a timely basis, if at all.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
The commercialization of XDEMVY and the development and potential commercialization of our product candidates will require substantial additional capital to fund expenses. In 2019 and 2020, we entered into the Eye and Derm Elanco Agreement and the All Human Uses Elanco Agreement, respectively. We have utilized these license rights in
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
CCPA and other state laws could impact our business activities depending on how they are interpreted and exemplify the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and protected health information. The CCPA may increase our compliance costs and potential liability, and similar laws have been proposed at the federal level and have been proposed and enacted in other states.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
As of December 31, 2024, we no longer qualified as an emerging growth company or a smaller reporting company and, as a result, are no longer able to avail ourselves of certain reduced reporting requirements applicable to emerging growth companies or smaller reporting companies, subject to applicable transition relief.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
On June 28, 2024, the last business day of the second quarter of 2024, the aggregate market value of the shares of our common stock held by non-affiliate stockholders exceeded $700.0 million. As a result, we became a large accelerated filer as of December 31, 2024, as defined in Rule 12b-2 under the Exchange Act, and ceased to qualify as an emerging growth company. Effective December 31, 2024, due to large accelerated filer status, we no longer qualify as a smaller reporting company and accordingly are not permitted to take advantage of the reduced reporting requirements for smaller reporting companies, subject to a transition period that allows us to use smaller reporting company scaled disclosure for our Annual
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
Report on Form 10-K for the year ending December 31, 2024. With the transition to becoming a large accelerated filer, we did not elect to use the smaller reporting company scaled disclosures.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
As a result of our loss of emerging growth company and smaller reporting company status, we expect our operating costs to increase as our compliance, reporting and other costs increase.
Read it in 10-K Feb 25, 2025 at sec.gov
RewordedRisk Factors
For example, in March 2024 2025, we completed a follow-on public offering of 3.3 approximately 3.2 million shares of our common stock at a public offering price of $32.00 $44.50 per share and, in lieu of common stock to a certain investor, pre-funded warrants to purchase 312,500 shares of our common stock at a price of $31.9999 per pre-funded warrant, share, for aggregate net proceeds of approximately $107.7 $134.8 million (after deducting underwriting discounts, commissions and other estimated offering-related expenses) and in 2023 we raised approximately $19.2 million, after deducting broker commissions and fees, through sales under our 2023 ATM Prospectus. expenses).
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
The 2024 Credit Facility provides for We did not draw on any of the three potential additional term loan tranches in principal amounts up to of $25.0 million, $50.0 million, and $50.0 million, million respectively, subject to customary conditions to funding and, in the case each of the last two tranches, achieving minimum net sales milestones, which may be requested expired on or prior to December 31, 2024, June 30, 2025 2025, and December 31, 2025, respectively. 2025.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
While the regulatory provisions that purported to affect the applicability of the best price and average manufacturer price exclusions of manufacturer-sponsored patient benefit programs, in the context of Certain pharmacy benefit managers ("PBM") (“PBM”) “accumulator” and "maximizer" “maximizer” programs that attempted to implement these regulations were invalidated by a court, but such programs may continue to negatively affect us in other ways.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Further, the IRA established a Medicare Part D Prescription Drug Program ("Medicare Part D") inflation rebate scheme, (with with the first rebate period taking place in the fourth quarter of 2022 through the third quarter of 2023, and a drug price negotiation program, under which the prices for Medicare units of certain high Medicare spend drugs and biologics without generic or biosimilar competition will be capped by reference to, among other things, a specified Non-FAMP, with the first negotiated prices to take effect in 2026.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
If we, or our manufacturing partners, are unable to successfully scale up the manufacture of XDEMVY or our product candidates in sufficient quality and quantity, the commercialization of XDEMVY or the development, testing and clinical trials of that product candidate may be delayed or become infeasible, and commercialization of XDEMVY or marketing approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Until such time as we can generate substantial revenue from product sales, including from XDEMVY, our only approved product, we We expect to finance our cash needs through existing capital balances, revenue from our net product sales, possible combinations of equity offerings, and debt financings, collaborations, strategic alliances and licensing arrangements.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Under this program, the manufacturer is obligated to make its covered drugs available for procurement on an FSS contract and charge a price to the Big Four agencies that is no higher than the Federal Ceiling Price (“FCP”), which is a price calculated pursuant to a statutory formula.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
The Given ongoing discussion with the FDA about our Lyme disease program, they agreed to our proposed approach for a Phase 2b 2 clinical trial, trial of TP-05 which would include several hundred subjects. subjects, with planned trial initiation expected in the second quarter of 2026.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
For example, in In March 2024 2024, we completed a follow-on public offering of approximately 3.3 million shares of our common stock at a public offering price of $32.00 per share and, in lieu of common stock to a certain investor, pre-funded warrants to purchase 312,500 shares of our common stock at a price of $31.9999 per pre-funded warrant, for aggregate net proceeds of approximately $107.7 million (after deducting underwriting discounts, commissions and other estimated offering-related expenses) and in 2023 we raised approximately $19.2 million, after deducting broker commissions and fees, through sales under our 2023 ATM Prospectus. expenses).
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
We While we have incurred significant generated revenue from the launch of XDEMVY® (lotilaner ophthalmic solution) 0.25%, we have continued to incur losses and negative cash flows from operations since our inception and anticipate that we could continue to incur significant expenses and potential losses for in the foreseeable future.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
We may not be granted patent term extension either in the U.S. or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements.
Read it in 10-K Feb 23, 2026 at sec.gov
Quiet changesRisk Factors
Our prior losses, combined with expected potential future losses, have had and will could continue to have an adverse effect on our accumulated deficit and working capital.
Read it in 10-K Feb 23, 2026 at sec.gov
Quiet changesRisk Factors
For example, we have established an internal infrastructure as well as an ECP-focused sales and distribution infrastructure to market XDEMVY and our product candidates in the U.S., and have substantially completed hiring in areas to support commercialization, including sales management, sales representatives, marketing, access and reimbursement, sales support and distribution.
Read it in 10-K Feb 23, 2026 at sec.gov
Quiet changesRisk Factors
We may need to obtain substantial additional funding to achieve our goals and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, reduce or eliminate our product development programs, commercialization efforts or other operations.
Read it in 10-K Feb 23, 2026 at sec.gov
Quiet changesRisk Factors
We expect our expenses to continue to increase substantially and we will require a larger amount of capital to fund our commercialization efforts, the development of our product candidates and the maintenance and expansion of our operations and capabilities.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
•Strengthened our leadership with the appointment of David E.I. Pyott, a renowned Biopharmaceutical leader and former Chief Executive Officer and Chairman of Allergan Inc., to the Board of Directors.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
◦Mr. Pyott joined our Board of Directors in February 2026 and brings decades of global leadership experience spanning innovative R&D, product development, and commercial execution. He was instrumental in transforming Allergan from a focused eye care business with approximately $1 billion in revenue into a global specialty pharmaceutical and medical device leader generating more than $7 billion in revenue.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
•Ongoing discussions continue with regulatory authorities in Japan on a potential path to approval of TP-03 for Demodex blepharitis. The Elara prevalence trial showed high prevalence and significant impact of Demodex blepharitis in Japan, consistent with U.S. findings.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
Recent global economic conditions have been marked by significant volatility and heightened trade tensions. In addition, persistent inflationary pressures, a prolonged higher interest rate environment, energy supply disruptions in certain regions, evolving trade policies, regulatory uncertainty, and ongoing and emerging geopolitical conflicts, including war, have contributed to regional and global macroeconomic challenges. These conditions have created uncertainty in global markets and may continue to impact economic conditions for an extended period.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
In July 2025, the OBBB Act was enacted in the U.S, which contains a broad range of tax reform provisions affecting businesses, including permitting the immediate expensing of domestic research and development expenditures. Provision for income taxes was $2.1 million for the year ended December 31, 2025, primarily due to state income tax expense resulting from states that do not conform to the OBBB Act and therefore continue to require the capitalization and amortization of domestic research and development expenditures. There was no provision for income taxes recorded during the year ended December 31, 2024.
Read it in 10-K Feb 23, 2026 at sec.gov
RemovedMD&A
•The expanded sales force deployed in the third quarter 2024 started to deliver meaningfully to the increased ECP utilization and prescription volumes reported for the fourth quarter 2024.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
•We activated a memorable and action-oriented Direct-to-Consumer ("DTC") campaign on streamlining platforms in the fourth quarter 2024 and initiated a trial-run on network televisions in January 2025, including spots on the Golden Globes, the GRAMMYs and the National Football League playoffs.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
◦The initial patient response from this campaign has been positive across multiple leading indicators, including the downloading of materials, taking the Demodex blepharitis quiz and utilizing the "find an eye doctor tool on the XDEMVY website.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
We expanded and strengthened our eye care leadership with two key appointments to our executive team and Board of Directors. Elizabeth Yeu, M.D. was appointed Chief Medical Officer in November 2024. Dr. Yeu is a distinguished ophthalmologist with more than two decades of experience who transitioned from her role as our Chief Medical Advisor and a member of our Board of Directors. Katherine H. Goodrich, M.D., MHS was appointed to our Board of Directors in November 2024. Dr. Goodrich is currently the Chief Medical Officer of Humana Inc., and brings decades of experience driving innovative and value-based initiatives designed to improve patient outcomes.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
In Japan, we expect to share results from a Demodex blepharitis prevalence study in the first half of 2025 and meet with Japanese regulatory authorities to help determine a regulatory path forward.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
The Chinese regulatory agency, National Medical Products Administration, accepted the New Drug Application ("NDA") submitted by our partner, Grand Pharmaceutical Group Ltd., for TP-03 for Demodex blepharitis.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
Recently, the economy has experienced downward pressure, and together with high rates of inflation and energy supply issues experienced in certain regions, war and geopolitical conflicts, have led to regional and/or global macroeconomic challenges, the effects of which may be of an extended duration.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
In addition, we may be exposed to credit risk on deposits at financial institutions to the extent our account balances exceed the amount insured by the Federal Deposit Insurance Corporation (“FDIC”). We maintain cash held in deposit at financial institutions in the U.S. While these deposits are insured by the FDIC in an amount up to $250,000 for any depositor, to the extent we hold cash deposits in amounts that exceed the FDIC insurance limitation, we may incur a loss in the event of a failure of any of the financial institutions where we maintain deposits. We invest our excess cash in highly liquid investments, including money market fund accounts, that are readily convertible into cash without penalty. We believe the Company is not exposed to significant credit risk due to the financial position of the depository institutions and the types of accounts we hold, but we will continue to monitor regularly and adjust, if needed, to mitigate risk, including any ongoing or new events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions.
Read it in 10-K Feb 25, 2025 at sec.gov
RewordedMD&A
To date date, we have financed our operations through private placements of preferred stock, convertible promissory notes, net proceeds from issuance of common stock in our Initial Public Offering ("IPO"), initial public offering (“IPO”), our subsequent follow-on public offerings in May 2022 (the "May “May 2022 Public Offering"), Offering”), August 2023 (the "August “August 2023 Public Offering"), and Offering”), March 2024 (the "March “March 2024 Public Offering", Offering”), and March 2025 (the “March 2025 Public Offering”, collectively the "Follow-On “Follow-On Public Offerings"), Offerings”), and our Open Market Sale AgreementTM (the "2023 “2023 ATM Prospectus"), Prospectus”), as well as proceeds from net product sales, our China Out-License, and drawdowns from the loan and security agreement (the “2024 Credit Facilities. Facility”) with funds associated with Pharmakon Advisors, LP (“Pharmakon”), and the previous loan and security agreement with Hercules Capital, Inc. and Silicon Valley Bank, a division of First Citizens Bank & Trust Company (the “2022 Credit Facility”, and collectively the “Credit Facilities”).
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Net cash provided by financing activities was $130.2 $143.4 million for the year ended December 31, 2023, 2025, and consisted of (i) $99.4 $134.8 million of net proceeds from the issuance of common stock from our August 2023 March 2025 Public Offering, (ii) $19.2 $6.3 million of net proceeds from common employee stock sold under the 2023 ATM Prospectus, option exercises, and (iii) $10.0 $2.3 million of proceeds from our 2022 Credit Facility, (iv) $1.0 million of proceeds from our ESPP, and (v) $0.6 million of proceeds from the exercise of vested employee stock options. Employee Stock Purchase Plan (“ESPP”).
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
The increase was primarily due to (i) $3.5 $8.9 million of increased indirect expenses related to payroll and personnel-related costs (including increased stock-based compensation expense of $1.0 $3.2 million) for employee additions to drive our product development initiatives, (ii) $0.7 $1.6 million of increased other indirect expenses, (iii) a $1.5 million increase in milestone expense related to our in-license agreements (see Note 9), and (iv) $1.2 $3.3 million of increased TP-03 early-stage programs, and (iv) $2.4 million of increased TP-04 program expenses.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
See the section titled "Risk Factors" for a further discussion of For additional information regarding the potential adverse impact effects of unfavorable global and geopolitical economic conditions on our business, results of operations and financial condition. condition, please see “Risk Factors” in Item 1A of Part I of this Annual Report on Form 10-K.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
The Given ongoing discussions with the FDA about our Lyme disease program, they agreed to our proposed approach for a Phase 2b 2 clinical trial, trial of TP-05 (an investigational oral tablet), which would include several hundred subjects. subjects with planned trial initiation expected in the second quarter of 2026.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
The AAOpt presentation, presentations, which combined the Ersa and Rhea trials Trials data in a pooled analysis, demonstrated that XDEMVY provided statistically significant and clinically meaningful improvements of the meibomian glands from baseline and when compared to vehicle. vehicle, including at least three times more glands secreting normal or clear liquid in patients treated with XDEMVY compared to vehicle at day 43.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
The 2024 Public Offering was In March 2025, we completed an underwritten follow-on public offering under the 2024 Shelf Registration Statement, Statement pursuant to which we sold 2,812,500 shares of our common stock, and, in lieu of common stock to a certain investor, pre-funded warrants to purchase 312,500 2,808,988 shares of our common stock.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
We have also completed, and/or have ongoing completed clinical trials for the potential treatment of in Demodex blepharitis in patients with Meibomian Gland Disease ("MGD"), (“MGD”), including the Ersa Phase 2a clinical trial involving XDEMVY, (the “Ersa Trial”), and the Rhea a pilot clinical trial (the “Rhea Trial”) involving an XDEMVY vehicle; vehicle.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
In January December 2025, we announced plans to initiate initiated a Phase 2 study in the second half of 2025 trial for the potential treatment of Ocular Rosacea. ocular rosacea with topline results expected in the first half of 2027.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
We expect to While we have generated revenue from the launch of XDEMVY, we could incur significant operating losses for in the foreseeable future, and for these losses to further increase, future as we expand our clinical development programs for our other product candidates and continue to commercialize XDEMVY.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
After review of this the Galatea trial data with the FDA and Key Opinion Leaders, key opinion leaders (“KOLs”), we decided to pursue development of TP-04 for the potential treatment for Ocular Rosacea. ocular rosacea, a highly prevalent and underserved eye disease with no FDA-approved therapy.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Until such time as we can generate significant revenue from product sales and achieve profitability, if ever, we We expect to finance our operations through existing capital balances, revenue from product sales, public equity or debt financings, or collaborations, strategic alliances, or licensing arrangements with third parties.
Read it in 10-K Feb 23, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TARS/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.